24 results about "Oxalomalic acid" patented technology

Electrolyte solution comprising a first lithium salt, a second lithium salt and a first additive, wherein the first lithium salt comprises at least lithium bis(fluorosulfonyl)imide and the second lithium salt is selected from the group consisting of lithium difluoro(oxalato)borate, lithium difluorobis(oxalato)phosphate and a combination thereof; and the first additive is methylenemethanedisulfonate.

The invention discloses a battery monomer, an isolating membrane, a preparation method of the isolating membrane, a battery device and a power utilization device, the battery monomer comprises the isolating membrane and electrolyte, and the isolating membrane comprises a porous base membrane; the coating is arranged on at least one side of the porous base membrane and comprises a polymer additive, and the polymer additive comprises a first functional group and a second functional group; the first functional group comprises one or more of bis (fluorosulfonyl) imino group, bis (trifluoromethyl) sulfonyl imino group, trifluoroboric acid group, hexafluorophosphoric acid group, sulfonic acid group, hexafluoroarsenate group, trifluoromethanesulfonic acid group, difluorophosphoric acid group, bis (oxalato) boric acid group, difluoro (oxalato) boric acid group, difluoro (oxalato) phosphoric acid group, tetrafluoro (oxalato) phosphoric acid group and imidazolyl; the second functional group comprises one or more of quaternary ammonium ions, pyrrolidinyl, pyrrolyl, piperidinyl, pyridyl and imidazolyl. The battery monomer has good dynamic performance; the invention provides the isolating membrane for realizing the beneficial effects of the battery monomer, the preparation method of the isolating membrane, the battery device and the power utilization device.

An electrolyte additive, a preparation method therefor, and an application thereof. The electrolyte additive comprises a halogen-substituted tris(oxalato)diborate, the halogen-substituted tris(oxalato)diborate having a structure as shown in formula I, where R1 and R2 are each independently selected from one of the halogens, and M+ are selected from one of the alkali metal ions. The halogen-substituted tris(oxalato)diborate has relatively good chemical stability and electrochemical stability, is used in an electrolyte of a secondary battery, and improves the thermal stability effect of a product. In addition, since the halogen-substituted tris(oxalato)diborate has more oxalate functional groups, the ion concentration in the electrolyte can be well adjusted, which can effectively improve the conductivity of an electrolyte, such that the voltage of a battery can be more easily maintained within a suitable range.

The present invention relates to use of a compound represented by formula (I) or an ester thereof or a pharmaceutically acceptable salt thereof in the treatment of a disease accompanied by fibrosis.

The invention relates to an oxalate hydrogenation catalyst carrier, a catalyst and a preparation method, and the method comprises the following steps: enabling gasified fly ash to electrostatically adsorb a cationic surfactant type pore-foaming agent, hydrolyzing tetraethyl orthosilicate under the action of the cationic surfactant and ammonia water, and forming a silicon dioxide shell layer on the surface of the gasified fly ash, after the cationic surface active agent is completely decomposed through calcination, a porous structure is formed on a silicon dioxide shell layer of the gasified fly ash to serve as an active center load; according to the method, the defect that strong acid / strong base is adopted in the traditional technology can be effectively avoided, meanwhile, compared with KCC-1, MCM-41, SBA-15 and other silicon dioxide carriers, the purpose of greatly reducing the carrier cost can be achieved on the premise that the conversion rate of dimethyl oxalate is as high as 98.61% through a catalyst prepared based on the carrier dipping active metal, and in addition, the method has the advantages that the cost of the carrier is greatly reduced. The gasified fly ash which is used as solid waste is also developed with high value.

The invention concerns an orally administrable pharmaceutical dosage form configured for targeted delivery to the distal part of the gastrointestinal tract of a human subject, wherein the pharmaceutical dosage form comprises lanthanum or a pharmaceutically acceptable salt or oxide thereof. The invention further relates to the pharmaceutical dosage form for use in the treatment of hyperoxaluria in a human subject, optionally wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria; and / or for use in the treatment of one or more of nephrolithiasis, nephrocalcinosis, or oxalosis in a human subject.

The application discloses a preparation method, a catalytic material and application of an oxalate-based nickel-iron MOF doped carbon nanotube catalytic material. The preparation method comprises the following steps: dispersing nickel nitrate hexahydrate, potassium trioxalate ferrate and carbon nanotubes into a methanol solution, stirring at room temperature after ultrasonic treatment to obtain a mixed solution with precipitates, centrifuging the obtained mixed solution, washing with methanol, and vacuum drying to obtain the oxalate-based nickel-iron MOF doped carbon nanotube catalytic material. The oxalate-based coordination is utilized to synthesize the oxalate-based bridged Ni-Fe bimetallic coordination polymer by one-step synthesis. The oxalate-based oxygen bridge bond participates in the transmission of the synergistic effect between the Ni-Fe bimetals. After the carbon nanotubes are doped, the active sites of the catalytic material are fully exposed, and the Ni-Fe bimetals connected by the oxygen bridge can fully exert the synergistic effect between the two.

The invention relates to the technical field of biochemical engineering, in particular to a preparation method of 4-(hydroxymethylphosphonyl)-2-oxobutyric acid, which comprises the following steps: S1) performing Claisen condensation reaction on a compound as shown in a formula I and oxalate as shown in a formula II under the action of an alkaline condensing agent to obtain a metal salt intermediate as shown in a formula III; and S2) contacting the metal salt intermediate shown in the formula III with aqueous acid to neutralize and desalt, and carrying out acidolysis to obtain the 4-(hydroxymethylphosphonyl)-2-oxobutyric acid shown in the formula IV. According to the present invention, the water-containing acid is adopted to remove the salt before the water-containing acid is adopted, after the Claisen condensation reaction is completed, the water-containing acid is added to replace the cations such as sodium ions in the alkaline condensing agent so as to generate the corresponding metal salt, and the metal salt is rapidly separated out in the solvent system, such that the salt forming particle size is effectively controlled, and the salt is easily filtered and removed; and acidizing and hydrolyzing the mother liquor to obtain the product 4-(hydroxymethylphosphonyl)-2-oxobutyric acid. The method has the characteristics of simplicity in operation, low energy consumption and the like.

The application belongs to the technical field of compound preparation, and particularly relates to a preparation method of an alkali metal salt of an oxalate chelate structure, at least comprising the following steps: mixing tris(trimethylsilyl) phosphate, an oxalate and a phosphorus-containing or boron-containing fluorine compound in a first organic solvent, stirring and heating to obtain lithium phosphate, trimethyl fluorosilane gas, and difluorobisoxalate phosphate or difluorooxalate borate, filtering the reaction solution to obtain lithium phosphate solid and a difluorobisoxalate phosphate solution or a difluorooxalate borate solution; adding a second organic solvent for recrystallization after concentration; and obtaining difluorobisoxalate phosphate or difluorooxalate borate solid after filtration, and drying the solid under reduced pressure to obtain a finished product. The process is simple, and the cost is low. By-products lithium phosphate, potassium fluoride and hexamethyldisiloxane can be directly sold as products after purification. Therefore, the application has an atomic utilization rate close to 100%, no invalid waste, less three-waste emissions, and is friendly to the environment.

This disclosure provides a process for preparing α-hydroxy esters by adding a vinyl Grignard reagent to an oxalate ester and then thiolated the resulting double bond. It also provides α-hydroxy esters and synthetic intermediates prepared according to the process disclosed herein, as well as compositions comprising said α-hydroxy esters.

The present application relates to hydrogen peroxide (H2O2) sensitive covalent cyclodextrin framework and its preparation method and application. Specifically, the covalent cyclodextrin framework is a cyclodextrin-metal organic framework with covalently linked peroxymonosulfate groups and / or covalently modified by phenylboronic acid ester cross-linking agent. The covalent cyclodextrin framework of the present application has hydrogen peroxide sensitivity, can reduce the level of hydrogen peroxide, and shows good antioxidant and anti-inflammatory capacity in vivo and in vitro. It can also play a synergistic therapeutic effect with drug molecules. The covalent cyclodextrin framework of the present application also has suitable biodegradability, good biological safety, and also has a large specific surface area for drug loading, and is an excellent drug carrier.

The invention relates to a chiral synthesis method of an S-citalopram intermediate, and belongs to the technical field of raw material medicine synthesis. The invention aims to overcome the defects in the prior art and provides a chiral synthesis method of a citalopram intermediate compound 3 so as to improve the resolution yield and reduce the production cost of raw material medicines. According to the present invention, the chiral reagent is utilized to induce the addition step of the Grignard reagent, the obtained compound 3 mainly comprises the S configuration, and the subsequent D-di-p-toluoyl tartaric acid resolution is performed so as to improve the S citalopram yield. According to the present invention, the chiral boron reagent is adopted to induce, such that the resolution efficiency is improved, and the cost of the escitalopram oxalate production process is reduced.

The invention relates to an acid-alkali synergistic molecular sieve carrier for a dimethyl oxalate decarbonylation reaction as well as a preparation method and application of the acid-alkali synergistic molecular sieve carrier. A preparation method of an acid-alkali synergistic molecular sieve carrier for dimethyl oxalate decarbonylation reaction comprises the following steps: (1) mixing a silicon source, an aluminum source, a trivalent metal M source, a template agent, an alkali source and water, and preparing gel; carrying out hydrothermal crystallization, filtering, washing and drying on the gel to obtain a molecular sieve of which the skeleton contains heteroatoms M; (2) roasting the molecular sieve in an oxygen-containing or inert atmosphere to remove the organic template agent to obtain a roasted molecular sieve; and (3) placing the roasted molecular sieve in an inert atmosphere containing water vapor, and carrying out heat treatment to obtain the acid-alkali synergistic molecular sieve carrier. According to the preparation method of the acid-alkali synergetic molecular sieve carrier for the dimethyl oxalate decarbonylation reaction, the defects that in an existing DMO decarbonylation catalyst carrier, acid and alkali active sites are spatially separated, functions are not synergetic, and stability is insufficient are overcome.

The present invention refers to recombinant forms of Glutamate-oxaloacetate transaminase (GOT1) fused to a Fc region to induce a neuroprotective effect in a mammal in need thereof. The chimeric protein originated with this fusion presents an improved pharmacokinetic profile while keeping similar specific activities when compared with the standard GOT enzyme. This enhanced stability of the protein in plasma is essential for the neuroprotective role of GOT on ischemic stroke events and other pathologies.

A nonaqueous solvent solution and a method for producing a nonaqueous electrolyte solution are provided. The nonaqueous solvent solution contains a nonaqueous solvent, a difluoro bis (oxalic acid) phosphate, and a tri (oxalic acid) phosphate, the concentration of the difluoro bis (oxalic acid) phosphate in the nonaqueous solvent solution being 10-50 mass%, and the ratio of the difluoro bis (oxalic acid) phosphate to the tri (oxalic acid) phosphate being 1 mol / mol of the difluoro bis (oxalic acid) phosphate to 1 mol / mol of the tri (oxalic acid) phosphate. And the amount of tris (oxalic acid) phosphate is 0.001 mol or more. The method for producing the non-aqueous electrolyte solution comprises adding a non-aqueous solvent solution to a reference non-aqueous electrolyte solution containing a solute and a solvent for the non-aqueous electrolyte solution.

The present application relates to the field of biotechnology, and particularly relates to a method for improving fermentation level of Bacillus subtilis oxalate decarboxylase based on SigA transcription switch. The present application is aimed at RNA polymerase housekeeping sigma factor SigA, and a transcription switch capable of accurately regulating expression level of the same is designed. The transcription switch is applied to fermentation of Bacillus subtilis oxalate decarboxylase, and oxalate decarboxylase can be stably and efficiently synthesized, so that the induction expression efficiency of oxalate decarboxylase is increased by 10 times compared with wild type strain. 3 -10 4 The present application provides a new design idea for efficient regulation of gene expression in the field of Bacillus subtilis metabolic engineering and synthetic biology, and the method for improving fermentation level of Bacillus subtilis oxalate decarboxylase has important application prospects in the fields of industrial fermentation of oxalate decarboxylase, degradation of industrial wastewater or oxalic acid pollution in agricultural product processing, degradation of oxalic acid pollution in soil and preparation of microbial preparation for degrading oxalic acid.

The invention provides a synthetic method of 4-amino-1-methyl-3-n-propyl-1H-pyrazole-5-formamide, and the synthetic method comprises the following steps of: taking 4-amino-1-methyl-3-n-propyl-1H-pyrazole-5-formamide as a raw material; according to the method, 2-pentanone and dimethyl oxalate are used as raw materials for condensation reaction, then ammonolysis and nitrosation are performed to obtain 3-(hydroxyimino)-2, 4-dicarbonyl methyl heptanoate, and then hydrazine hydrate cyclization, methylation and reduction are performed to obtain a target product. The reaction avoids using dangerous processes such as mixed acid nitration and the like, and is mild in reaction condition, simple in operation steps and suitable for industrial production.

The invention discloses an electrochemically reconstructed bismuth-based nano-catalyst as well as a preparation method and application thereof, and belongs to the technical field of catalysts. The catalyst comprises a substrate and a Bi nanosheet arranged on the substrate, wherein the Bi nanosheet is generated by loading a Bi2O3-x nanosheet precursor prepared by a solvothermal-calcination method on the substrate through electrochemical reconstruction. Compared with the prior art, the method has the advantages that a precursor Bi2O3-x nanosheet is reduced into a metal state Bi nanosheet through an electrochemical reconstruction method, and the crystalline phase of metal Bi is kept unchanged when the metal state Bi nanosheet is electrically reduced in an acid solution. The Faraday efficiency and partial current density of the catalyst in the reaction of preparing glycollic acid by electrocatalytic oxalic acid reduction are improved, namely, the catalyst has high selectivity and reaction activity.

The application discloses a synthesis method of indole-2-carboxylic acid, which is suitable for industrial production and comprises the following steps: (1) condensation: mixing o-nitrotoluene, diethyl oxalate and sodium ethoxide ethanol solution, raising to 75-85 DEG C and reacting for 1.5-3 hours, adding into water, stirring for 0.5-1.5 hours, removing ethanol, decoloring, filtering, adjusting the pH of the filtrate to 1-2, and obtaining an intermediate; (2) reduction: adding methanol to the intermediate, adding Raney nickel, raising to 55-65 DEG C, adding hydrogen and reacting, lowering to room temperature, filtering, removing methanol, lowering to 0-5 DEG C and preserving for 1-2 hours, and filtering to obtain a crude product; and (3) purification: adding water to the crude product, adjusting the pH to 8-9, decoloring, filtering, adjusting the pH to 2-3, precipitating a solid, filtering, and drying the filter cake.

The invention provides a preparation method of an amidoxime functionalized metal organic framework as well as a product and application of the amidoxime functionalized metal organic framework, the method comprises the following steps: (1) mixing 2, 5-dibromoterephthalic acid, a zirconium source and a coordination regulator in a solvent, and reacting to obtain a metal organic framework UiO-66-2Br; (2) mixing the UiO-66-2Br and a cyanation reagent in a solvent, and reacting to obtain a metal organic framework UiO-66-2CN; (3) mixing the hydroxylamine salt, an alkaline reagent and UiO-66-2CN in a solvent, and reacting to obtain an amidoxime functionalized metal organic framework UiO-66-2AO; the hydroxylamine salt comprises any one or a combination of at least two of hydroxylamine nitrate, hydroxylamine sulfate or hydroxylamine oxalate. The UiO-66-2AO has high adsorption capacity for uranyl ions in a wide pH range, and efficient separation of rare earth ions and uranyl ions is achieved.

The invention relates to a process for the production of an oxalate polyester (co)polymer, comprising the use of bis(2-methoxyphenyl) oxalate to introduce oxalate monomer units into the polymer chain, comprising at least steps (a) and (b):(a) an esterification / transesterification step wherein at least one dicarboxylic acid or an ester derivative thereof is / are reacted with an excess of at least one diol compound to form a pre-polycondensation product comprising alcohol end groups, or otherwise producing such pre-polycondensation product;(b) a polymerization step comprising polycondensation of the product of step (a) with bis(2-methoxyphenyl) oxalate in a molar amount that is equal to between about 0.4 to about 0.6 equivalents of the molar amount of alcohol end groups in the pre-polycondensation product of step (a).The process is an efficient process for the production of novel and existing oxalate polyester (co)polymers, also with high molecular weight, and optionally without the need for the addition of a metal catalyst.

The invention relates to the field of medical pathology, in particular to a fading kit and a fading method after combined staining of biopsy samples AB and PAS, and the kit comprises a reagent A potassium permanganate buffer solution, a reagent B oxalic acid solution, a reagent C buffer washing solution and a reagent D ammonia water solution. The invention provides a reagent combination and a kit which are simple and convenient to operate, thorough in fading effect and small in damage to tissue antigens and DNA, a method for jointly dyeing gastric mucosa biopsy samples AB and PAS and then thoroughly fading is utilized, subsequent pathological diagnosis of samples with small samples and few tumor cells is facilitated, good sample reuse capability is provided, and the kit is suitable for clinical application. The preparation method is a reagent preparation and method with actual requirements.

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the HAO1 gene are provided. Compositions and methods for treating subjects having primary hyperoxaluria type 1 (PH1), are provided.

The invention discloses a programmed cascade response nano drug delivery platform as well as a preparation method and application thereof. Raft-base PEG-5000 is used as an initiator and is respectively subjected to polymerization reaction with an acid response monomer C7A and a blood vessel disrupting agent DMXAA connected through an ester bond or podophyllotoxin connected through an oxalate bond to prepare two random copolymers. The copolymer is dissolved in tetrahydrofuran, the solution is slowly and dropwise added into a phosphate buffer solution containing glucose oxidase, a vesicle structure is formed through self-assembly, wrapping of the glucose oxidase is achieved, and therefore the nano-drug delivery platform with the programmed cascade response characteristic is constructed. According to the invention, through a programmed cascade response mechanism, synergistic cooperation of time sequence regulation and control of drug release and a treatment function is realized, and the drug has multiple stimulation responsiveness, drug effect controllability and immunoregulation ability, is suitable for multi-mode combined treatment of solid tumors, and has a clear technical implementation path and application value.